Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics
Isabella Presch, Senior Medical Director Rare diseases, Advanced therapies and Pediatrics at Fortrea, shared a post on LinkedIn:
“A welcome step toward greater regulatory clarity in genome-editing therapeutics:
The continued advancement of genome-editing technologies will depend not only on scientific innovation, but also on the evolution of regulatory science.
Clear expectations for assessing off-target editing, chromosomal integrity, and genome-wide effects can help establish a common framework for safety evaluation, supporting both patient protection and the efficient development of transformative therapies for rare and genetic diseases.
The FDA‘s draft guidance, ‘Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing (NGS),” provides a scientifically rigorous framework for evaluating off-target editing, genomic integrity, sequencing methodologies, and bioinformatic analyses in support of genome-editing programs.
This guidance represents an important step in harmonizing expectations around the use of NGS-based methods to assess genome-editing risks.
Importantly, the FDA is currently seeking stakeholder feedback, with the public comment period open until 14 July 2026 offering sponsors, investigators, translational scientists, genomic technology developers, and bioinformatics experts a valuable opportunity to help shape the future regulatory framework for genome-editing therapies.”
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 14:09Stephen Alerhand: Acute Pulmonary Embolism vs Chronic Pulmonary Hypertension
-
Nov 15, 2026, 10:32Ibrahim Gwarzo: Identifying Care Gaps and Emergency Pain Delays in Sickle Cell Disease at APHA 2026
-
Nov 15, 2026, 10:17Ify Osunkwo: How the Sickle Cell Community Can Influence FDA Drug Development Priorities
-
Nov 15, 2026, 10:11Ahmed Abdelsalam: Why Matching ABO and RhD Groups Does Not Guarantee Crossmatch Compatibility
-
Nov 15, 2026, 10:06Asma Khalil: New British Society for Haematology Guidance on Paediatric and Neonatal Transfusion
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research